ReviewChemistryOpen2026
Chemical and Technological Aspects of Magnetic Particles for Cancer Liquid Biopsy Applications.
Review in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Recent progress in molecular diagnostics has been strongly influenced by advances in magnetic bead (MB) chemistry. Synthetic strategies for MB fabrication play a critical role in defining their size, physicochemical properties, and nano- or microscale architectures, which ultimately determine their analytical performance. The efficiency of MBs in liquid biopsy depends on the architecture of their components, including magnetic core, surface functionalization, as well as the integration of recognition ligands. This review highlights the recent developments in MB design for the selective capture, identification, and quantification of cancer biomarkers in liquid biopsy applications. It also summarizes the advantages and limitations of commercially available MB platforms and critically evaluates emerging systems reported in the literature. By comparing current technologies, this review discusses major advances as well as remaining translational bottlenecks, providing guidance for the rational design of next-generation MBs for liquid biopsy. The latter is an emerging technology increasingly used in precision oncology for molecular profiling to support cancer diagnosis, prognosis, and the selection of personalized treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.